• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SVP, Bus Dev, General Counsel Imam Tariq covered exercise/tax liability with 3,501 shares and was granted 15,000 shares, increasing direct ownership by 47% to 36,078 units (SEC Form 4)

    1/13/26 4:08:09 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $LSTA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Imam Tariq

    (Last) (First) (Middle)
    C/O LISATA THERAPEUTICS, INC.
    110 ALLEN ROAD, 2ND FLOOR

    (Street)
    BASKING RIDGE NJ 07920

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    LISATA THERAPEUTICS, INC. [ LSTA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Bus Dev, General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    01/09/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/09/2026 A 15,000(1) A $0 39,579(2) D
    Common Stock 01/09/2026 F 1,401(3) D $1.97 38,178(2) D
    Common Stock 01/09/2026 F 840(3) D $1.97 37,338(2) D
    Common Stock 01/09/2026 F 747(3) D $1.97 36,591(2) D
    Common Stock 01/09/2026 F 513(3) D $1.97 36,078(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $1.97 01/09/2026 A 7,000 01/09/2026(4) 01/09/2036 Common Stock 7,000 $0 7,000 D
    Explanation of Responses:
    1. Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
    2. Includes 17,750 unvested restricted stock.
    3. Shares withheld as payment of a tax liability on vesting of restricted stock.
    4. One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.
    Remarks:
    Tariq Imam 01/13/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LSTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LSTA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LSTA
    SEC Filings

    View All

    Lisata Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

    1/27/26 8:27:26 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC14D9C filed by Lisata Therapeutics Inc.

    SC14D9C - LISATA THERAPEUTICS, INC. (0000320017) (Subject)

    1/21/26 9:19:48 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

    8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)

    1/21/26 8:58:41 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    $LSTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

    BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical Co., Ltd. ("Qilu"). The original agreement, negotiated and implemented with CEND Therapeutics and assumed by Lisata as part of its acquisition of CEND Therapeutics in 2022, granted Qilu exclusive rights to develop and commercialize certepetide, Lisata's proprietary iRGD cyclic peptide product

    1/27/26 8:00:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

    Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. ("Kuva"), a privately-held company. Pursuant to the terms and conditions of the term

    1/21/26 7:00:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapi

    11/6/25 4:05:00 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    $LSTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Mazzo David J was granted 81,000 shares and covered exercise/tax liability with 41,096 shares, increasing direct ownership by 15% to 311,890 units (SEC Form 4)

    4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

    1/13/26 4:09:54 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    SVP, Fin/Treas, Chief Actg Off Nisco James was granted 15,000 shares and covered exercise/tax liability with 6,180 shares, increasing direct ownership by 38% to 32,311 units (SEC Form 4)

    4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

    1/13/26 4:08:56 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    SVP, Bus Dev, General Counsel Imam Tariq covered exercise/tax liability with 3,501 shares and was granted 15,000 shares, increasing direct ownership by 47% to 36,078 units (SEC Form 4)

    4 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)

    1/13/26 4:08:09 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    $LSTA
    Leadership Updates

    Live Leadership Updates

    View All

    Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

    Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to lead development efforts to advance GATC's AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026 BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. ("GATC"), a leading tech-bio company leve

    6/17/25 8:00:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

    BASKING RIDGE, N.J. and HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Kuva Labs, a wholly owned subsidiary of Mi2 Holdings, LLC ("Kuva"), are pleased to announce a global collaboration and license agreement. Under the terms of this agreement Kuva gains access to Lisata's iRGD cyclic peptide product candidate, certepetide, as a targeting and enhanced delivery agent to be used with Kuva's NanoMark™ platform technology. This combination creates a new class of advanced magnetic resonance (MR) imaging

    12/3/24 8:30:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

    BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. Bevacizumab has previously demonstrated efficacy in treating endometriosis; however, the required dosage levels are associated with systemic side effects, limiting

    10/28/24 8:30:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    $LSTA
    Financials

    Live finance-specific insights

    View All

    Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapi

    11/6/25 4:05:00 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

    BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the live conference call, please refer to the dial-in information provided below. Conference Call Dial-in information: Participant Toll-Free dial: (800) 715-9871Participant Toll/Int'l dial:

    10/30/25 8:00:00 AM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care

    Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the second quarter ended June 30, 2025. "We continued to advance our clinical development portfolio and partnering initiatives during the second quarter of 2025," st

    8/7/25 4:05:00 PM ET
    $LSTA
    Misc Health and Biotechnology Services
    Health Care